Press

PharmAla Biotech to supply University of California Clinical Trial with LaNeo™ MDMA

Oct 4 • 2 min read

PharmAla Biotech (CSE: MDMA) is gratified to have been selected as the MDMA manufacturing partner for a human MDMA trial at a campus of the University of California. The University of California system encompasses 10 campuses across the State of California; This is the first US-based Clinical Trial to utilize PharmAla’s LaNeo™ MDMA. “The UC System is the location for some…

KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers

Oct 4 • 5 min read

Braxia Scientific Corp, (CSE: BRAX | OTC: BRAXF | FWB: 4960) a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is thrilled to announce the expanded availability of treatments offered by KetaMD, Inc. in Florida. KetaMD is a wholly owned subsidiary providing access to at-home ketamine…

Universal Ibogaine Undertaking Offering of Convertible Debt Securities and Common Shares

Oct 4 • 3 min read

Universal Ibogaine Inc.(TSXV:IBO), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it is in process of finalizing an offering of convertible debt securities. The Offering will consist of “Secured Guarantee Convertible Notes” which will bear interest at 8% (payable quarterly) and have a maturity of 3 years from…

PharmaDrug Advances Programs in Oncology and Infectious Disease Through Completion of cGMP Drug Substance Manufacturing

Oct 4 • 9 min read

PharmaDrug Inc. (CSE: PHRX | OTCQB: LMLLF), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company has now completed cGMP manufacturing of a multi-kilogram lot of cepharanthine-2HCl for use in the final drug product production of PD-001, its patented,…

Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin

Oct 4 • 5 min read

Tryp Therapeutics, Inc. (CSE: TRYP | OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the World Intellectual Property Organization (WIPO) published their international patent application (PCT/IB2022/052347) covering the intravenous administration of psilocybin and psilocin. The PCT application, titled “Improved Methods For The Use of…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441